The response rates are not uniform for all patients. A favorable response can be expected in patients with genotype 2 and 3, possibly those with a lower viral load, women, those under the age of 40, and those who have a favorable histology to begin with. The role of gender becomes insignificant if you control for the body weight, meaning that it may be a matter of getting the correct dose to the patient.